KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Treasury Shares: 2010-2024

Historic Treasury Shares for Biomarin Pharmaceutical (BMRN) over the last 5 years, with Dec 2024 value amounting to $4.5 million.

  • Biomarin Pharmaceutical's Treasury Shares fell 3.55% to $4.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $4.5 million, marking a year-over-year decrease of 3.55%. This contributed to the annual value of $4.5 million for FY2024, which is 3.55% down from last year.
  • As of Q4 2024, Biomarin Pharmaceutical's Treasury Shares stood at $4.5 million, which was down 3.55% from $4.7 million recorded in Q4 2023.
  • Over the past 5 years, Biomarin Pharmaceutical's Treasury Shares peaked at $4.7 million during Q4 2023, and registered a low of $126,710 during Q1 2020.
  • For the 3-year period, Biomarin Pharmaceutical's Treasury Shares averaged around $4.6 million, with its median value being $4.5 million (2024).
  • Its Treasury Shares has fluctuated over the past 5 years, first spiked by 756.66% in 2021, then declined by 3.55% in 2024.
  • Quarterly analysis of 5 years shows Biomarin Pharmaceutical's Treasury Shares stood at $518,000 in 2020, then soared by 756.66% to $4.4 million in 2021, then grew by 1.85% to $4.5 million in 2022, then increased by 4.07% to $4.7 million in 2023, then decreased by 3.55% to $4.5 million in 2024.
  • Its last three reported values are $4.5 million in Q4 2024, $4.7 million for Q4 2023, and $4.5 million during Q4 2022.